Petra Loid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Petra Loid has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Outi Mäkitie
Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
6 shared publications Mari Muurinen
2 shared publications- Alexandra F. Freeman
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
1 shared publication - Alexey Koval
Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
1 shared publication - Alice Costantini
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Amy P. Hsu
National Institute of Allergy and Infectious Diseases, National Institutes of Health 19 Laboratory of Clinical Immunology and Microbiology Bethesda, MD
1 shared publication
Latest Publications
- Open Access
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Delayed diagnosis of skeletal dysplasia in a girl with cartilage-hair hypoplasia
Short stature is the most common reason for endocrinological investigations during childhood. With the expanding spectrum of recognized genetic causes for abnormal growth, establishing the correct diagnosis is often challenging. We present a 12-year-old girl who was first evaluated for short stature (<3rd percentile) and short fingers at age 2 years. Skeletal radiographs showed mild long bone metaphyseal abnormalities. She had slightly thin hair, unilateral elbow dislocations, and genu varum but no hematologic abnormalities or signs of immunodeficiency. Growth hormone testing and other endocrine investigations were normal. At age 12 years, when her height was −3.0 SD score, skeletal dysplasia was considered, and genetic testing revealed compound heterozygosity for 2 RMRP variants (n.97_98dup and n.-25_-12dup), confirming the diagnosis of cartilage-hair hypoplasia (CHH), a recessive skeletal dysplasia. Retrospective review of early radiographs showed that diagnostic features were present already at the first assessment. The described patient is the first reported case of CHH in Greece. The delayed diagnosis led to several unnecessary investigations. This case highlights the importance of considering skeletal dysplasia in children with short stature. Early diagnosis of CHH is important for careful follow-up because of increased risk for immunodeficiency and malignancies.
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Open AccessDelayed diagnosis of skeletal dysplasia in a girl with cartilage-hair hypoplasia
Short stature is the most common reason for endocrinological investigations during childhood. With the expanding spectrum of recognized genetic causes for abnormal growth, establishing the correct diagnosis is often challenging. We present a 12-year-old girl who was first evaluated for short stature (<3rd percentile) and short fingers at age 2 years. Skeletal radiographs showed mild long bone metaphyseal abnormalities. She had slightly thin hair, unilateral elbow dislocations, and genu varum but no hematologic abnormalities or signs of immunodeficiency. Growth hormone testing and other endocrine investigations were normal. At age 12 years, when her height was −3.0 SD score, skeletal dysplasia was considered, and genetic testing revealed compound heterozygosity for 2 RMRP variants (n.97_98dup and n.-25_-12dup), confirming the diagnosis of cartilage-hair hypoplasia (CHH), a recessive skeletal dysplasia. Retrospective review of early radiographs showed that diagnostic features were present already at the first assessment. The described patient is the first reported case of CHH in Greece. The delayed diagnosis led to several unnecessary investigations. This case highlights the importance of considering skeletal dysplasia in children with short stature. Early diagnosis of CHH is important for careful follow-up because of increased risk for immunodeficiency and malignancies.
- 5 August 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-11
Short stature and response to growth hormone treatment in CUL3-related neurodevelopmental disorder
Introduction Recent research has expanded the spectrum of genetic causes for growth failures. Patients with CUL3-related neurodevelopmental disorder (NDD) present with variable phenotypic manifestations and growth retardation has been observed in some of these patients. Case Presentation We present two families with NDD and variable degree of short stature. The proband in Family 1 had short stature (-3.0 SDS), developmental delay, learning difficulties and autism spectrum disorder. Whole exome sequencing (WES) revealed a novel likely pathogenic heterozygous nonsense CUL3 variant c.420C>G, p.Tyr140Ter. The variant was also identified in her non-identical twin sister, who presented with short stature and NDD, and in their father, who had NDD and epilepsy but normal height. The proband and her sister were treated with growth hormone (GH) with good response. The proband and his brother in Family 2 presented with short stature during childhood, NDD and facial dysmorphism. WES identified a heterozygous likely pathogenic nonsense CUL3 variant c.442C>T, p.Arg148Ter in the proband and his brother. The variant was inherited from their mother, who had facial dysmorphism and hypertension but normal height. Conclusion CUL3-related NDD can be associated with growth retardation. We observed a good response to GH therapy in two of our patients with short stature. Our finding expands the spectrum of disease-causing variants in CUL3 and demonstrates variable intra-familial clinical expressivity.
- 5 August 2025
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-11
Short stature and response to growth hormone treatment in CUL3-related neurodevelopmental disorder
Introduction Recent research has expanded the spectrum of genetic causes for growth failures. Patients with CUL3-related neurodevelopmental disorder (NDD) present with variable phenotypic manifestations and growth retardation has been observed in some of these patients. Case Presentation We present two families with NDD and variable degree of short stature. The proband in Family 1 had short stature (-3.0 SDS), developmental delay, learning difficulties and autism spectrum disorder. Whole exome sequencing (WES) revealed a novel likely pathogenic heterozygous nonsense CUL3 variant c.420C>G, p.Tyr140Ter. The variant was also identified in her non-identical twin sister, who presented with short stature and NDD, and in their father, who had NDD and epilepsy but normal height. The proband and her sister were treated with growth hormone (GH) with good response. The proband and his brother in Family 2 presented with short stature during childhood, NDD and facial dysmorphism. WES identified a heterozygous likely pathogenic nonsense CUL3 variant c.442C>T, p.Arg148Ter in the proband and his brother. The variant was inherited from their mother, who had facial dysmorphism and hypertension but normal height. Conclusion CUL3-related NDD can be associated with growth retardation. We observed a good response to GH therapy in two of our patients with short stature. Our finding expands the spectrum of disease-causing variants in CUL3 and demonstrates variable intra-familial clinical expressivity.
- 8 April 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (7) , 436-440
Short stature, brachydactyly and joint contractures associated with novel FBN2 variants in two families
Background: Fibrillinopathies comprise allelic disorders with opposing phenotypes. Pathogenic variants in fibrillin-2, encoded by FBN2, have mainly been associated with congenital contractural arachnodactyly but in a few cases also with brachydactyly. Methods and results: We recruited two families with index patients presenting with short stature (heights ≤3 SD scores), brachydactyly, joint contractures and facial dysmorphism as major features. In Family 2, the proband and father also had carpal tunnel syndrome. Radiographs showed signs of mild skeletal dysplasia with short long bones, brachydactyly and mild metaphyseal and vertebral irregularity. Whole genome sequencing revealed novel variants in the FBN2 gene that segregated with the phenotype: in Family 1, a novel heterozygous missense variant c.4862G>A, p.(Cys1621Tyr) and in Family 2, a novel heterozygous deletion of exons 9–11. The missense variant affects a highly conserved residue and is predicted to be deleterious by most in silico tools. The FBN2 deletion affects a well-conserved region and leads to loss of the transforming growth factor β binding-like 2 domain and part of the calcium-binding epidermal growth factor-like domain. Conclusion: Our findings suggest that short stature and mild skeletal dysplasia might be part of the spectrum of FBN2-related phenotypes. The study supports the role of FBN2 variants in growth failure and expands the molecular spectrum of FBN2 variants.
- 8 April 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (7) , 436-440
Short stature, brachydactyly and joint contractures associated with novel FBN2 variants in two families
Background: Fibrillinopathies comprise allelic disorders with opposing phenotypes. Pathogenic variants in fibrillin-2, encoded by FBN2, have mainly been associated with congenital contractural arachnodactyly but in a few cases also with brachydactyly. Methods and results: We recruited two families with index patients presenting with short stature (heights ≤3 SD scores), brachydactyly, joint contractures and facial dysmorphism as major features. In Family 2, the proband and father also had carpal tunnel syndrome. Radiographs showed signs of mild skeletal dysplasia with short long bones, brachydactyly and mild metaphyseal and vertebral irregularity. Whole genome sequencing revealed novel variants in the FBN2 gene that segregated with the phenotype: in Family 1, a novel heterozygous missense variant c.4862G>A, p.(Cys1621Tyr) and in Family 2, a novel heterozygous deletion of exons 9–11. The missense variant affects a highly conserved residue and is predicted to be deleterious by most in silico tools. The FBN2 deletion affects a well-conserved region and leads to loss of the transforming growth factor β binding-like 2 domain and part of the calcium-binding epidermal growth factor-like domain. Conclusion: Our findings suggest that short stature and mild skeletal dysplasia might be part of the spectrum of FBN2-related phenotypes. The study supports the role of FBN2 variants in growth failure and expands the molecular spectrum of FBN2 variants.
- Open Access
- 10 December 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (6) , 628-636
Rare gene variants and weight loss at 10 years after sleeve gastrectomy and gastric bypass - a randomized clinical trial
- 10 December 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (6) , 628-636
Open AccessRare gene variants and weight loss at 10 years after sleeve gastrectomy and gastric bypass - a randomized clinical trial
- Open Access
- 22 October 2024
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 99 (1) , 49-56
Novel Insights: A Novel PHIP Variant in a Family with Severe Early-Onset Obesity
Introduction: Severe childhood obesity can be caused by pathogenic variants in several genes involved in monogenic and syndromic obesity. Recently, heterozygous variants in pleckstrin homology domain interacting protein (PHIP) have been identified in patients with obesity as part of Chung-Jansen syndrome. Case Presentation: The index patient is a 5-year-old boy with severe obesity since 1 year of age, developmental delay, facial dysmorphism, and behavior problems. Whole-exome sequencing identified a novel missense variant in PHIP (c.3182C>A, p.Ala1061Glu) in the index patient. Further genetic testing in family members revealed segregation of the same PHIP variant in the brother and mother, who both presented with severe childhood obesity and developmental delay or learning difficulties. The PHIP missense variant was predicted pathogenic by multiple in silico tools and affects a highly conserved residue. Conclusion: Early-onset obesity may be monogenic. Our finding expands the spectrum of disease-causing variants in PHIP and demonstrates variable intrafamilial clinical expressivity and severity. Screening for PHIP variants should be included in genetic testing in patients with severe early-onset obesity.
- 22 October 2024
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 99 (1) , 49-56
Open AccessNovel Insights: A Novel PHIP Variant in a Family with Severe Early-Onset Obesity
Introduction: Severe childhood obesity can be caused by pathogenic variants in several genes involved in monogenic and syndromic obesity. Recently, heterozygous variants in pleckstrin homology domain interacting protein (PHIP) have been identified in patients with obesity as part of Chung-Jansen syndrome. Case Presentation: The index patient is a 5-year-old boy with severe obesity since 1 year of age, developmental delay, facial dysmorphism, and behavior problems. Whole-exome sequencing identified a novel missense variant in PHIP (c.3182C>A, p.Ala1061Glu) in the index patient. Further genetic testing in family members revealed segregation of the same PHIP variant in the brother and mother, who both presented with severe childhood obesity and developmental delay or learning difficulties. The PHIP missense variant was predicted pathogenic by multiple in silico tools and affects a highly conserved residue. Conclusion: Early-onset obesity may be monogenic. Our finding expands the spectrum of disease-causing variants in PHIP and demonstrates variable intrafamilial clinical expressivity and severity. Screening for PHIP variants should be included in genetic testing in patients with severe early-onset obesity.
- 20 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6715) , eadd8947
Germline mutations in a G protein identify signaling cross-talk in T cells
Humans with monogenic inborn errors responsible for extreme disease phenotypes can reveal essential physiological pathways. We investigated germline mutations in GNAI2 , which encodes G αi2 , a key component in heterotrimeric G protein signal transduction usually thought to regulate adenylyl cyclase–mediated cyclic adenosine monophosphate (cAMP) production. Patients with activating G αi2 mutations had clinical presentations that included impaired immunity. Mutant G αi2 impaired cell migration and augmented responses to T cell receptor (TCR) stimulation. We found that mutant G αi2 influenced TCR signaling by sequestering the guanosine triphosphatase (GTPase)–activating protein RASA2, thereby promoting RAS activation and increasing downstream extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT S6 signaling to drive cellular growth and proliferation.
- 20 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6715) , eadd8947
Germline mutations in a G protein identify signaling cross-talk in T cells
Humans with monogenic inborn errors responsible for extreme disease phenotypes can reveal essential physiological pathways. We investigated germline mutations in GNAI2 , which encodes G αi2 , a key component in heterotrimeric G protein signal transduction usually thought to regulate adenylyl cyclase–mediated cyclic adenosine monophosphate (cAMP) production. Patients with activating G αi2 mutations had clinical presentations that included impaired immunity. Mutant G αi2 impaired cell migration and augmented responses to T cell receptor (TCR) stimulation. We found that mutant G αi2 influenced TCR signaling by sequestering the guanosine triphosphatase (GTPase)–activating protein RASA2, thereby promoting RAS activation and increasing downstream extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT S6 signaling to drive cellular growth and proliferation.
- Open Access
- 12 June 2017
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (8) , 3029-3039
Copy Number Variants Are Enriched in Individuals With Early-Onset Obesity and Highlight Novel Pathogenic Pathways
Context: Only a handful of genetic causes for childhood obesity have been identified to date. Copy number variants (CNVs) are known to contribute to obesity, both syndromic (15q11.2 deletions, Prader-Willi syndrome) and non-syndromic (16p11.2 deletions) obesity. Objective: To study the contribution of CNVs to early-onset obesity and evaluate the expression of candidate genes in subcutaneous adipose tissue. Design and Setting: A case-control study in a tertiary academic center. Participants: CNV analysis was performed on 90 subjects with early-onset obesity and 67 normal-weight controls. Subcutaneous adipose tissue from BMI-discordant siblings was used for gene expression analyses. Main Outcome Measures: We used custom high-density array comparative genomic hybridization with exon resolution in 1989 genes including all known obesity loci. Expression levels of candidate genes were assessed using microarray analysis of mRNA from subcutaneous adipose tissue. Results: We identified rare CNVs in 17 (19%) subjects with obesity and two (3%) controls. In three cases (3%) the identified variant involved a known syndromic lesion (22q11.21 duplication, 1q21.1 deletion and 16p11.2 deletion, respectively) while others were novel. Seven CNVs in ten families were inherited and segregated with obesity. Expression analysis of 37 candidate genes showed discordant expression for ten genes (PCM1, EFEMP1, MAMLD1, ACP6, BAZ2B, SORBS1, KLF15, MACROD2, ATR and MBD5). Conclusions: Rare CNVs contribute possibly pathogenic alleles to a substantial fraction of children with early-onset obesity. Involved genes may provide new insights to pathogenic mechanisms and involved cellular pathways. These findings highlight the importance of CNV screening in children with early-onset obesity.
- 12 June 2017
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (8) , 3029-3039
Open AccessCopy Number Variants Are Enriched in Individuals With Early-Onset Obesity and Highlight Novel Pathogenic Pathways
Context: Only a handful of genetic causes for childhood obesity have been identified to date. Copy number variants (CNVs) are known to contribute to obesity, both syndromic (15q11.2 deletions, Prader-Willi syndrome) and non-syndromic (16p11.2 deletions) obesity. Objective: To study the contribution of CNVs to early-onset obesity and evaluate the expression of candidate genes in subcutaneous adipose tissue. Design and Setting: A case-control study in a tertiary academic center. Participants: CNV analysis was performed on 90 subjects with early-onset obesity and 67 normal-weight controls. Subcutaneous adipose tissue from BMI-discordant siblings was used for gene expression analyses. Main Outcome Measures: We used custom high-density array comparative genomic hybridization with exon resolution in 1989 genes including all known obesity loci. Expression levels of candidate genes were assessed using microarray analysis of mRNA from subcutaneous adipose tissue. Results: We identified rare CNVs in 17 (19%) subjects with obesity and two (3%) controls. In three cases (3%) the identified variant involved a known syndromic lesion (22q11.21 duplication, 1q21.1 deletion and 16p11.2 deletion, respectively) while others were novel. Seven CNVs in ten families were inherited and segregated with obesity. Expression analysis of 37 candidate genes showed discordant expression for ten genes (PCM1, EFEMP1, MAMLD1, ACP6, BAZ2B, SORBS1, KLF15, MACROD2, ATR and MBD5). Conclusions: Rare CNVs contribute possibly pathogenic alleles to a substantial fraction of children with early-onset obesity. Involved genes may provide new insights to pathogenic mechanisms and involved cellular pathways. These findings highlight the importance of CNV screening in children with early-onset obesity.
- Open Access
- 27 April 2015
- Published by Wiley in Acta Paediatrica
- Vol. 104 (7) , 707-712
A persistently high body mass index increases the risk of atopic asthma at school age
Aim: Being overweight has been associated with the risk of developing childhood asthma, but studies have produced conflicting results, for example with regard to possible links to allergic diseases. This study aimed to explore the relationship between body mass index (BMI) and school‐age asthma.Methods: Data were obtained from a prospective, longitudinal study of 5044 children born in western Sweden. The parents answered questionnaires at six months and one, four‐and‐a‐half and eight years of age. The response rate to the final questionnaire at the age of eight was just over 80%. BMI was adjusted for age and gender, and a high BMI was defined as the 85th percentile and above.Results: A multivariate analysis showed an independently increased risk of doctor‐diagnosed asthma among children with a persistently high BMI, both in infancy and at school age, with an adjusted odds ratio (aOR) of 2.9 and a 95% confidence interval (CI) of 1.3–6.4. In addition, persistently high BMI was associated with an increased risk of atopic asthma (aOR 4.7, 95% CI 2.0–11.0).Conclusion: A persistently high BMI during childhood increased the risk of doctor‐diagnosed asthma at school age. The increased risk of atopic asthma suggests an effect mediated via the immune system.
- 27 April 2015
- Published by Wiley in Acta Paediatrica
- Vol. 104 (7) , 707-712
Open AccessA persistently high body mass index increases the risk of atopic asthma at school age
Aim: Being overweight has been associated with the risk of developing childhood asthma, but studies have produced conflicting results, for example with regard to possible links to allergic diseases. This study aimed to explore the relationship between body mass index (BMI) and school‐age asthma.Methods: Data were obtained from a prospective, longitudinal study of 5044 children born in western Sweden. The parents answered questionnaires at six months and one, four‐and‐a‐half and eight years of age. The response rate to the final questionnaire at the age of eight was just over 80%. BMI was adjusted for age and gender, and a high BMI was defined as the 85th percentile and above.Results: A multivariate analysis showed an independently increased risk of doctor‐diagnosed asthma among children with a persistently high BMI, both in infancy and at school age, with an adjusted odds ratio (aOR) of 2.9 and a 95% confidence interval (CI) of 1.3–6.4. In addition, persistently high BMI was associated with an increased risk of atopic asthma (aOR 4.7, 95% CI 2.0–11.0).Conclusion: A persistently high BMI during childhood increased the risk of doctor‐diagnosed asthma at school age. The increased risk of atopic asthma suggests an effect mediated via the immune system.